Drug Profile
Research programme: protein therapeutics - Inpharmatica/Merck Serono
Alternative Names: Protein therapeutics research programme - Inpharmatica/Merck SeronoLatest Information Update: 13 Mar 2008
Price :
$50
*
At a glance
- Originator Galapagos NV; Merck Serono
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 08 Jan 2007 Serono is now called Merck Serono
- 05 Jan 2007 Serono has been acquired by Merck KGaA
- 09 Sep 2003 Inpharmatica and Serono have extended their research collaboration